Fig. 3: BCL6 knockout aggravates HFD-induced hepatic steatosis. | Cell Death & Disease

Fig. 3: BCL6 knockout aggravates HFD-induced hepatic steatosis.

From: B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36

Fig. 3

A Schematic image of the generation of a liver-specific BCL6-CKO mouse (BCL6-CKO) strain. B Mouse genotyping was confirmed by PCR. C Protein expression of BCL6 in the liver of flox and CKO mice. D Bodyweight, (E) liver weight, (F) LW/BW, and (G) food intake of the BCL6-CKO and BCL6-flox mice at 16 weeks post-HFD administration (n = 6/group). H Representative images of H&E (upper) and oil red O (bottom) staining of liver tissues from the BCL6-CKO and BCL6-flox mice fed an HFD for 16 weeks. Scale bar, 100 μm. I Total cholesterol, J triglyceride, K NEFA, and L ALT and M AST levels in the livers from the BCL6-CKO and BCL6-flox mice fed an HFD for 16 weeks. (n = 6/group). N Representative images of immunohistochemistry staining of F4/80 and Sirian red staining of liver tissues from two group mice. Scale bar, 100 μm. Hepatic mRNA levels of (O) IL-6 and TNFα, (P) COL1α1and αSMA from two group mice fed an HFD for 16 weeks (n = 6/group). Data represent the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 and N.S. indicates no significance between the two indicated groups.

Back to article page